Literature DB >> 6271019

Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers.

D Naber, D Pickar, R M Post, D P Van Kammen, R N Waters, J C Ballenger, F K Goodwin, W E Bunney.   

Abstract

The authors measured total opioid activity by radioreceptor assay in the CSF of 41 normal subjects and 89 unmedicated psychiatric patients, including schizophrenic, schizoaffective, depressed, and manic diagnostic groups. Schizophrenic men had significantly lower levels of opioid activity than the normal men, although these levels did not significantly differ from levels of other male patients. The authors observed higher opioid activity during mania than during depression in paired samples for 4 manic-depressive patients. beta-Endorphin immunoreactivity in a subsample of the same subjects was no different in the patient group than in the normal group, suggesting that the differences in CSF opioid activity between schizophrenic men and normal patients may be related to opioids other than beta-endorphin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271019     DOI: 10.1176/ajp.138.11.1457

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  The effect of neuroleptic treatment and of high dosage diazepam therapy on beta-endorphin immunoreactivity in plasma of schizophrenic patients.

Authors:  C Gramsch; H M Emrich; S John; S Haas; H Beckmann; M Zaudig; D von Zerssen
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

2.  Beta-endorphin-immunoreactivity in the ventricular CSF and plasma of comatose patients.

Authors:  E Hamel; B Allolio
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 4.  Enkephalins and Endorphins. Clinical, pharmacological and therapeutic implications.

Authors:  D L Copolov; R D Helme
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

Review 5.  Psychoneuroendocrine research in depression. I. Hormone levels of different neuroendocrine axes and the dexamethasone suppression test.

Authors:  R Rupprecht; K P Lesch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

Authors:  R Weizman; A Weizman; S Tyano; G Szekely; B A Weissman; Y Sarne
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

8.  Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.

Authors:  M Zech; B Bogerts
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

9.  Evaluation of bile salt hydrolase inhibitor efficacy for modulating host bile profile and physiology using a chicken model system.

Authors:  Wenjing Geng; Sarah L Long; Yun-Juan Chang; Arnold M Saxton; Susan A Joyce; Jun Lin
Journal:  Sci Rep       Date:  2020-03-18       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.